Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Renal Cell
Dose-Response Relationship, Drug
Female
Hepatocyte Growth Factor
Humans
Infusions, Intravenous
Kidney Neoplasms
Male
Middle Aged
Survival Analysis
Treatment Outcome
authors with profiles
Walter M. Stadler